GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (LSE:RUA) » Definitions » EPS (Diluted)

RUA Life Sciences (LSE:RUA) EPS (Diluted) : £0.00 (TTM As of Sep. 2024)


View and export this data going back to 2002. Start your Free Trial

What is RUA Life Sciences EPS (Diluted)?

RUA Life Sciences's Earnings per Share (Diluted) for the six months ended in Sep. 2024 was £0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was £0.00.

RUA Life Sciences's EPS (Basic) for the six months ended in Sep. 2024 was £0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was £0.00.

RUA Life Sciences's EPS without NRI for the six months ended in Sep. 2024 was £0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was £0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 19.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was -6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, RUA Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 76.30% per year. The lowest was -140.50% per year. And the median was -3.70% per year.


RUA Life Sciences EPS (Diluted) Historical Data

The historical data trend for RUA Life Sciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences EPS (Diluted) Chart

RUA Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.08 -0.09 -0.09 -0.04

RUA Life Sciences Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.04 -0.05 -0.01 0.01

Competitive Comparison of RUA Life Sciences's EPS (Diluted)

For the Medical Devices subindustry, RUA Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RUA Life Sciences's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's PE Ratio falls into.



RUA Life Sciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

RUA Life Sciences's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.44-0)/33.547
=-0.04

RUA Life Sciences's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.636-0)/62.060
=0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RUA Life Sciences  (LSE:RUA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


RUA Life Sciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


RUA Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
2 Drummond Crescent, Ayrshire, Scotland, Irvine, GBR, KA11 5AN
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.

RUA Life Sciences Headlines

No Headlines